Clinical Trials Logo

Cerebral Adrenoleukodystrophy clinical trials

View clinical trials related to Cerebral Adrenoleukodystrophy.

Filter by:
  • None
  • Page 1

NCT ID: NCT06030648 Recruiting - Clinical trials for Cerebral Adrenoleukodystrophy

MT2022-01: MSCs for ALD

Start date: August 28, 2023
Phase: Phase 1
Study type: Interventional

This is a single-institution study to evaluate the use of intravenously administered allogeneic, 3rd party mesenchymal stem cells (IV-MSC) in patients with active, cerebral adrenoleukodystrophy (CALD), as a bridge to hematopoietic stem cell transplant or gene therapy, or in patients who are too advanced for gene therapy or HSCT. The intervention will occur in the time between diagnosis of active CALD and transplant which is currently 8-12 weeks.

NCT ID: NCT04528706 Active, not recruiting - Clinical trials for Cerebral Adrenoleukodystrophy

A Clinical Study in Male Pediatric Patients With Cerebral X-linked Adrenoleukodystrophy (Cald) to Assess the Effects of MIN-102 Treatment on Disease Progression Prior to Human Stem Cell Transplant (HSCT)

NEXUS
Start date: September 13, 2019
Phase: Phase 2
Study type: Interventional

An Open-Label, multicenter study in male pediatric patients with cerebral x-linked adrenoleukodystrophy (cald) to assess the effects of MIN-102 treatment on disease progression prior to human stem cell transplant (HSCT)

NCT ID: NCT03789721 Recruiting - Clinical trials for Adrenoleukodystrophy

Adrenoleukodystrophy National Registry Study

Start date: May 1, 2019
Phase:
Study type: Observational [Patient Registry]

The aim of this registry to understand the natural history and disease progression in ALD and potentially develop bio-markers using the biospecimens collected using this registry.

NCT ID: NCT03367546 Terminated - Sickle Cell Disease Clinical Trials

Haploidentical Allogeneic Hematopoietic Stem Cell Transplantation (HaploHCT) Following Reduced Intensity Conditioning (RIC) for Selected High Risk Non-Malignant Diseases

Start date: July 2, 2018
Phase: Phase 2
Study type: Interventional

This is a Phase II study for the use of T-cell replete reduced intensity conditioning (RIC) haploidentical donor allogeneic hematopoietic cell transplantation (HaploHCT) for individuals with high-risk non-malignant diseases who lack a suitable HLA-matched sibling donor.

NCT ID: NCT02410239 Withdrawn - Clinical trials for Cerebral Adrenoleukodystrophy

MT2014-14 IT-MSC for Advanced Cerebral Adrenoleukodystrophy (cALD)

Start date: June 2015
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the maximum tolerated dose (MTD) of mesenchymal stem cells (IT-MSC) in patients with active, advanced cerebral adrenoleukodystrophy (cALD).